Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix.

Between April 1979 and January 1982, 331 patients were included in a study to establish whether misonidazole (MISO) had any effect as an adjuvant to radiotherapy in the treatment of squamous cell carcinoma of the uterine cervix (FIGO Stage IIb, III, and IVa). Patients were randomized to receive either MISO (12 g/m2 applied within 6 weeks) or placebo. This was given in conjunction with each institution's normal radiotherapy schedule and thus varied with regard to external and intracavitary irradiation.

Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases.

Thirty-three cases of primary adenocarcinoma localized to the fallopian tubes were analyzed according to prognostic factors such as depth of infiltration, tumor differentiation, and lymph vessel invasion. Fifteen patients (45, 5%) died of recurrence within 5 years. Only for positive vessel invasion was the survival significance worse.